The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 5:43 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #19. Bristol-Myers Squibb iPierian, Inc.

Acquirer: Bristol-Myers Squibb (NYSE:BMY)
Acquiree: iPierian, Inc.
Details: Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise.

Bristol-Myers Squibb SEC Filing Email Alerts Service


Open the BMY Page at The Online Investor »

Company Name: 
Bristol-Myers Squibb Co.
Website: 
www.bms.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BMY: 
127
Total Market Value Held by ETFs: 
$7.74B
Total Market Capitalization: 
$74.66B
% of Market Cap. Held by ETFs: 
10.37%
 

Open the BMY Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.00 out of 4)
42nd percentile
(ranked lower than approx. 58% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 19 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.